Immunization with human papillomavirus type 16 (HPV16) oncoprotein- loaded dendritic cells as well as protein in adjuvant induces MHC class I- restricted protection to HPV16-induced tumor cells

Cancer Research

Volumn 58, Issue 4, 1998, Pages 724-731

  De Bruijn, Marloes L H ^a,b   Schuurhuis, Danita H ^a   Vierboom, Michel P M ^a   Vermeulen, Hans ^a   De Cock, Karin A J ^a   Ooms, Marlies E ^a   Ressing, Maaike E ^a   Toebes, Mireille ^a   Franken, Kees L M C ^a   Drijfhout, Jan Wouter ^a   Ottenhoff, Tom H M ^a   Offringa, Rienk ^a   Melief, Cornelis J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ALLELE; ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CELL KILLING; CELL PROTECTION; CELL TRANSFORMATION; DENDRITIC CELL; EFFECTOR CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; WART VIRUS;

ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FREUND'S ADJUVANT; HISTOCOMPATIBILITY ANTIGENS CLASS I; MICE; MICE, INBRED BALB C; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; TUMOR VIRUS INFECTIONS;

EID: 0032520073     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Germain, R. N. The ins and outs of antigen processing and presentation. Nature (Lond.), 322: 687-689, 1986.
2. Rock, K. L., Gamble, S., and Rothstein, L. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science (Washington DC), 249: 918-921, 1990.
3. Reimann, J., Böhm, W., and Schirmbeck, R. Alternative processing pathways for MHC class I-restricted epitope presentation to CD8+ cytotoxic T lymphocytes. Biol. Chem. Hoppe-Seyler, 375: 731-736, 1994.
4. Ulmer, J. B., Donnelly, J. J., and Liu, M. A. Presentation of an exogenous antigen by major histocompatibility complex class I molecules. Eur. J. Immunol., 24: 1590-1596, 1994.
5. Martinez-Kinader, B., Lipford, G. B., Wagner, H., and Heeg, K. Sensitization of MHC class I-restricted T cells to exogenous proteins: evidence for an alternative class I-restricted antigen presentation pathway. Immunology, 86: 287-295, 1995.
6. Staerz, U. D., Karasuyama, H., and Garner, A. M. Cytotoxic T lymphocytes against a soluble protein. Nature (Lond.), 329: 449-451, 1987.
7. Schirmbeck, R., Zerrahn, J., Kuhrober, A., Kury, A., Deppert, W., and Reimann, J. Immunization with soluble simian virus 40 large T antigen induces a specific response of CD3+ CD4- CD8+ cytotoxic T lymphocytes in mice. Eur. J. Immunol., 22: 759-766, 1992.
8. Raychaudhuri, S., Tonks, M., Carbone, F. R., Ryskamp, T., Morrow, W. J. W., and Hanna, N. Induction of antigen-specific class I-restricted cytotoxic cells by soluble proteins in vivo. Proc. Natl. Acad. Sci. USA, 89: 8308-8312, 1992.
9. Reddy, R., Zhou, F., Nair, S., Huang, L., and Rouse, B. T. In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. J. Immunol., 148: 1585-1589, 1992.
10. Schirmbeck, R., Böhm, W., and Reimann, J. Injection of detergent-denatured ovalbumin primes class I-restricted cytotoxic T cells in vivo. Eur. J. Immunol., 24: 2068-2072, 1994.
11. Bachmann, M. F., Hengartner, H., and Zinkernagel, R. M. Immunization with recombinant protein: conditions for cytotoxic T cell and/or antibody induction. Med. Microbiol. Immunol., 183: 315-324, 1994.
12. Bachmann, M. F., Kündig, T. M., Freer, G., Li, Y., Kang, C. Y., Bishop, D. H., Hengartner, H., and Zinkernagel, R. M. Induction of protective cytotoxic T cells with viral proteins. Eur. J. Immunol., 24: 2228-2236, 1994.
13. Hariharan, K., Braslawsky, G, Black, A., Raychaudhuri, S., and Hanna, N. The induction of cytotoxic T cells and tumor regression by soluble antigen formulation. Cancer Res., 55: 3486-3489, 1995.
14. Ke, Y., Ying, L., and Kapp, J. A. Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses. Eur. J. Immunol., 25: 549-553, 1995.
15. Schirmbeck, R., Deml, L. Melber, K., Wolf, H., Wagner, R., and Reimann, J. Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens. Vaccine, 13: 857-865, 1995.
16. Jondal, M., Schirmbeck, R., and Reimann, J. MHC class I-restricted CTL responses to exogenous antigens. Immunity, 5: 295-302, 1996.
17. Steinman, R. M. The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol., 9: 271-296, 1991.
18. Inaba, K., Young, J. W., and Steinman, R. M. Direct activation of CD8+ cytotoxic T lymphocytes by dendritic cells, J. Exp. Med., 166: 182-194, 1987.
19. Macatonia, S. E., Taylor, P. M., Knight, S. C., and Askonas, B. A. Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses. J. Exp. Med., 169: 1255-1264, 1989.
20. De Bruijn, M. L. H., Nieland, J. D., Schumacher, T. N. M., Ploegh, H. L., Kast, W. M., and Melief, C. J. M. Mechanisms of induction of primary virus-specific cytotoxic T lymphocyte responses. Eur. J. Immunol., 22: 3013-3020, 1992.
21. Romani, N., Koide, S., Crowley, M., Witmer-Pack, M., and Livingstone, A. M. Presentation of exogenous protein antigen by dendritic cells to T cell clones. Intact protein is best presented by immature epidermal Langerhans cells. J. Exp. Med., 169: 1169-1178, 1989.
22. De Bruijn, M. L. H., Nieland, J. D., Harding, C. V., and Melief, C. J. M. Processing and presentation of intact hen egg-white lysozyme by dendritic cells. Eur. J. Immunol., 22: 2347-2352, 1992.
23. Sallusto, F., and Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor α. J. Exp. Med., 179: 1109-1118, 1994.
24. Bachmann, M. F., Lutz, M. B., Layton, G. T, Harris, S. J., Fehr, T., Rescigno, M., and Ricciardi-Castagnoli, P. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur. J. Immunol., 26: 2595-2600, 1996.
25. Shen, Z., Reznikoff, G., Dranoff, G., and Rock, K. L. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol., 158: 2723-2730, 1997.
26. De Bruijn, M. L. H., Schuurhuis, D. H., Vermeulen, H., de Cock, K. A. J., and Melief, C. J. M. Processing of exogenous protein antigen by murine dendritic cells for presentation to cytotoxic T lymphocytes. Adv. Exp. Med. Biol., 417: 213-220, 1997.
27. zur Hausen, H. Papillomaviruses in the pathogenesis of anogenital cancer. Virology, 184: 9-13, 1991.
28. Crawford, L. Prospects of cervical cancer vaccines. Cancer Surv., 16: 215-229, 1993.
29. Sheil, A. G. Development of malignancy following renal transplantation in Australia and New Zealand. Transplant. Proc., 24: 1255-1259, 1992.
30. Wu, T-C. Immunology of the human papilloma virus in relation to cancer. Curr. Opin. Immunol., 6: 746-754, 1994.
31. von Knebel Doeberitz, M., Oltersdorf, T., Schwarz, E., and Gissmann, L. Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res., 48: 3780-3786, 1988.
32. Meneguzzi, G. C., Cerni, C., Kieny, M. P., and Lathe, R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology, 181: 62-69, 1991.
33. Chen, L., Thomas, E. K., Hu, S-L., Hellström, I., and Hellström, K. E. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc. Natl. Acad. Sci. USA, 88: 110-114, 1991.
34. Chen, L., Ashe, S., Brady, W. A., Hellstrom, L, Hellstrom, K. E., Ledbetter, J. A., McGowan, P., and Linsley, P. S. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 71: 1093-1102, 1992.
35. Feltkamp, M., Smits, H., Vierboom, M., Minnaar, R. P., de Jongh, B. M., Drijfhout, J-W., ter Schegget, J., Melief, C. J. M., and Kast, W. M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol., 23: 2242-2249, 1993.
36. Gao, L., Chain, B., Sinclair, C., Crawford, L., Zhou, J., Morris, J., Zhu, X., and Stauss, H. Immune response to human papillomavirus type 16 E6 in a live vaccinia vector. J. Gen. Virol., 75: 157-164, 1994.
37. d mice. Scand. J. Immunol., 42: 557-563, 1995.
38. Tarpey, I., Stacey, S. N., McIndoe, A., and Davies, D. H. Priming in vivo and quantification in vitro of class I MHC-restricted cytotoxic T cells to human papilloma virus type 11 early proteins (E6 and E7) using immunostimulating complexes (ISCOMs). Vaccine, 14: 230-236, 1996.
39. Boursnell, M. E. G., Rutherford, E., Hickling, J. K., Rollinson, E. A., Munro, A. J., Rolley, N., McLean, C. S., Borysiewicz, L. K., Vousden, K., and Inglis, S. C. Construction and characterization of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine, 14: 1485-1494, 1996.
40. Borysiewicz, L. K., Fiander, A., Nimako, M., Man, S., Wilkinson, G. W. G., Westmorland, A. S., Evans, M., Satcy, S. N., Boursnell, M. E. G., Rutherford, E., Hickling, J. K., and Inglis, S. C. A recombinant vaccine virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet, 347: 1523-1527, 1996.
41. Toes, R. E. M., Offringa, R., Blom, R. J. J., Melief, C. J. M., and Kast, W. M. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA. 93: 7855-7860, 1996.
42. Moore, M. W., Carbone, F. R., and Bevan, M. J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell. 54: 777-785, 1988.
43. Studier, F. W., Rosenberg, A. H., Dunn, J. J., and Dubendorff, J. W. Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol., 185: 60-89, 1990.
44. Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., and Steinman, R. M. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med., 176: 1693-1702, 1992.
45. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J. M., Ildstad, S. T., Kast, W. M., DeLeo, A. B., and Lotze, M. T. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med., 1: 1297-1302, 1995.
46. Nolan, G. P., Fiering, S., Nicolas, J-F., and Herzenberg, L. A. Fluorescence-activated cell analysis and sorting of viable mammalian cells based on β-D-galactosidase activity after transduction of Escherichia coli lacZ. Proc. Natl. Acad. Sci. USA, 85: 2603-2607, 1988.
47. Sanderson, S., and Shastri, N. LacZ-inducible, antigen/MHC-specific T cell hybrids. Int. Immunol., 6: 369-376, 1994.
48. Traversari, C., van der Bruggen, P., Van den Eynde, B., Hainaut, P., Lemoine, C., Ohta, N., Old, L., and Boon, T. Transfection and expression of a gene encoding a human melanoma antigen recognized by autoiogous cytolytic T lymphocytes. Immunogenetics, 35: 145-152, 1992.
49. Dialynas, D. P., Quan, Z. S., Wall, K. A., Pierres, A., Quintas, J., Loken, M. R., Pierres, M., and Fitch, F. W. Characterization of the murine T cell surface molecule, designated L3T4, identified by the monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecules. J. Immunol., 131: 2445-2451, 1983.
50. Sarmiento, M., Glasebrook, A. L., and Fitch, F. W. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J. Immunol., 125: 2665-2672, 1980.
51. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engelman, E. G., and Levy, R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2: 52-58, 1996.
52. Mayordomo, J. I., Loftus, D. J., Sakamoto, H., De Cesare, C. M., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E., and DeLeo, A. B. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med., 183: 1357-1365, 1996.
53. Inaba, K., Metlay, J. P., Crowley, M. T., and Steinman, R. M. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J. Exp. Med., 172: 631-640, 1990.
54. Paglia, P., Chiodoni, C., Rodolfo, M., and Colombo, M. P. Murine dendritic cells loaded in vitro with soluble protein prime CTL against tumor antigen in vivo. J. Exp. Med., 183: 317-322, 1996.
55. Stauss, H. J., Davies, H., Sadnikova, E., Chain, B., Horowitz, N., and Sinclair, C. Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus. Proc. Natl. Acad. Sci. USA, 89: 7871-7875, 1992.